Aviceda Therapeutics
PrivateLast Round
Series C
Jan 7, 2025
Total Funding Raised
$211.75M
Company Overview
Aviceda Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series C round in January 2025.
Aviceda Therapeutics is a biotechnology company that develops next-generation immunomodulators using its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform to address chronic, non-resolving inflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aviceda Therapeutics Comparables
Compare Aviceda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Annexon Biosciences | 81% | |
| Ashvattha Therapeutics | 80% | |
| Complement Therapeutics GmbH | 79% |
For institutional investors. Book with your work email.
Aviceda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 7, 2025 | ||||
| VC Round | May 31, 2024 | ||||
| VC Round | May 19, 2023 | ||||
| VC Round | Mar 28, 2022 | ||||
| Seed | Sep 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aviceda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C, VC Round |
| Enavate Sciences | Series C, VC Round |
| Aberdeen Group plc | Series C |
| TCG Crossover | Series C, VC Round |
| Omega Funds | Series C, VC Round |
| Digitalis Ventures | Series C, VC Round |
| Blue Owl Capital | Series C, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2025
Dr. Emmett T. Cunningham, Jr. joins the board.
- Jan 8, 2025
AVD-104 is a clinical-stage candidate for geographic atrophy.
For institutional investors. Book with your work email.
Aviceda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aviceda Therapeutics's valuation, stock price, and market status.
Is Aviceda Therapeutics a public or private company?
Aviceda Therapeutics is a private company.
What is the current stock price of Aviceda Therapeutics?
Aviceda Therapeutics is a private company, so its shares have no public market price. Caplight tracks Aviceda Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aviceda Therapeutics worth (valuation)?
Valuation information for Aviceda Therapeutics is not publicly available.
Can I buy Aviceda Therapeutics stock?
Aviceda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aviceda Therapeutics's last funding round?
Aviceda Therapeutics's most recent funding round was Series C on January 7, 2025.
Who are the main investors in Aviceda Therapeutics?
Key investors in Aviceda Therapeutics include TCG Crossover, Omega Funds, TCG Crossover.
Will Aviceda Therapeutics IPO soon?
No public IPO plans have been announced for Aviceda Therapeutics.
How can I track Aviceda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aviceda Therapeutics's shares on secondary markets.